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Introduction {#acn3785-sec-0001}
============

Voltage gated sodium channels (VGSCs) are heterotrimers, composed of one pore‐forming *α* subunit and two nonpore‐forming *β* subunits.[1](#acn3785-bib-0001){ref-type="ref"} *β*1 subunits are ubiquitously expressed throughout the nervous system with wide subcellular localization in neurons where they associate with many, if not all, VGSC *α* subunits.[2](#acn3785-bib-0002){ref-type="ref"} *β*1 subunits regulate VGSC *α* subunit trafficking, expression, and gating, associate with and modulate some voltage‐gated potassium channels, and play nonconducting roles in neuronal pathfinding and fasciculation as immunoglobulin superfamily cell adhesion molecules (Ig‐CAMs).[2](#acn3785-bib-0002){ref-type="ref"}

Variants in VGSC genes are linked to the developmental and epileptic encephalopathies (DEEs).[3](#acn3785-bib-0003){ref-type="ref"} Dravet syndrome (DS) is a severe DEE predominantly linked to haploinsufficiency of *SCN1A,* encoding the VGSC *α* subunit Na~v~1.1. Results from mouse models suggest that epilepsy in DS initiates from disinhibition through reduced sodium current density in cortical and hippocampal parvalbumin‐positive GABAergic interneurons.[4](#acn3785-bib-0004){ref-type="ref"} While the majority of DS patients have *de novo*, heterozygous variants in *SCN1A*, inherited, homozygous loss‐of‐function variants in *SCN1B,* encoding the VGSC *β*1/*β*1B subunits, also result in DS, or a DS‐like DEE.[5](#acn3785-bib-0005){ref-type="ref"}, [6](#acn3785-bib-0006){ref-type="ref"} *Scn1b* null mice are a DS model, with severe seizures, ataxia, and 100% lethality prior to weaning.[5](#acn3785-bib-0005){ref-type="ref"} *Scn1b* null mice have neuronal pathfinding defects in brain that precede the onset of seizures.[7](#acn3785-bib-0007){ref-type="ref"} Based on these results, we proposed that epilepsy in this model is of neurodevelopmental origin due to the loss of *β*1‐mediated Ig‐CAM function.[7](#acn3785-bib-0007){ref-type="ref"} In the related *Scn1b‐*p.C121W homozygous mouse model, which has a similar DS‐like phenotype, neuronal hyperexcitability was postulated to arise from the developmental loss of *β*1‐mediated Ig‐CAM function.[8](#acn3785-bib-0008){ref-type="ref"} In support of this hypothesis, variants in other neurodevelopmental CAMs, for example, protocadherin 7 and 19,[3](#acn3785-bib-0003){ref-type="ref"}, [8](#acn3785-bib-0008){ref-type="ref"} are also associated with epilepsy.

Because *β*1 subunits are multifunctional Ig‐CAMs and channel modulators, it is important to understand what roles altered development play in epileptogenesis in response to *Scn1b* loss‐of‐function. Here, we test the hypothesis that altered neuronal development is necessary for epileptogenesis in the *Scn1b* model of DS. We show that severe seizures and SUDEP occur following *Scn1b* deletion in adult mice that had developed normally, suggesting that epileptogenesis in *SCN1B*‐DS does not result from defective brain development.

Methods {#acn3785-sec-0002}
=======

Animals {#acn3785-sec-0003}
-------

Experiments were performed in accordance with NIH guidelines and approved by the University of Michigan Institutional Animal Care and Use Committee. *Scn1b* ^*Fl/Fl*^ mice, on the C57BL/6J background,[9](#acn3785-bib-0009){ref-type="ref"} were crossed with *Slick‐H* mice (JAX Tg(Thy1‐cre/ERT2,‐EYFP)HGfng/PyngJ, stock \#012708) received on the (C57BL/6J x CBA)F1 background and backcrossed to C57BL/6J, to generate *Slick‐H*/*Scn1b* ^Fl/Fl^ and *Slick‐H*/*Scn1b* ^E/E^ mice. Tamoxifen (TMX, Sigma‐Aldrich) was dissolved in sunflower oil + 2% ethanol at a final concentration of 10 *μ*g/*μ*L. 10 *μ*L of TMX solution or vehicle per g mouse weight were administered intraperitoneal (IP) once per day for 4 consecutive days.

Immunohistochemistry {#acn3785-sec-0004}
--------------------

P60 *Slick‐H* mice, treated with TMX 10 days prior, were anesthetized with isoflurane and transcardially perfused with \~10 mL of PBS followed by \~10 mL of 4% paraformaldehyde (PFA). Tissues were postfixed overnight in 4% PFA, then cryoprotected in 10% sucrose followed by 30% sucrose overnight, flash frozen in 2‐methylbutane, and stored at −80°C. 20 *μ*m coronal brain sections were cut on a Leica cryostat and stored at −20°C until processing for immunohistochemistry.

For immunohistochemistry, sections at the same locations relative to Bregma for each animal were dried and postfixed for 10 min with 4% PFA, washed three times for 5 min each with 0.05 mol/L phosphate buffer (PB), and incubated in PBTGS blocking buffer (10% goat serum, 0.3% Triton X‐100, 0.1 mol/L PB) for ≥2 h in a humidified chamber. Sections were then incubated with primary antibodies (diluted in PBTGS) overnight in a humidified chamber and washed 3 times for 10 min with 0.1 mol/L PB. Primary antibodies were anti‐GABA (rabbit, Sigma‐Aldrich, 1:400), anti‐GFP (chicken, Invitrogen, 1:400), and anti‐CTIP2 to identify cortical layer V/VI neurons (rat, Abcam, 1:250). From this point forward, all steps were performed in the dark to minimize photobleaching of secondary antibodies. Sections were incubated with goat anti‐chicken AlexaFluor‐488, goat anti‐rat AlexaFluor‐647, and/or goat anti‐rabbit AlexaFluor‐594‐conjugated secondary antibodies (Invitrogen, diluted in PBTGS) for 2 h, washed three times for 10 min in 0.1% PB, incubated with DAPI for 20 min, dried, and then coverslips were mounted using ProLong Gold anti‐fade reagent (Invitrogen).

Sections were imaged using a Nikon A1R confocal microscope with Nikon NIS‐Elements AR software located in the UM Department of Pharmacology using a 20 × 0.75 NA dry objective. Confocal images spanning 10 *μ*m were acquired at 0.9 *μ*m intervals and flattened using maximum signal for analysis. Images were processed and analyzed using NIH‐ImageJ, and figures were assembled using Adobe Photoshop.

EEG Implantation {#acn3785-sec-0005}
----------------

*Slick‐H/Scn1b* ^Fl/Fl^, *Slick‐H* negative*/Scn1b* ^Fl/Fl^ *,* and *Slick‐H/Scn1b* ^E/E^ mice were implanted at P42 to 70 with 6 EEG electrodes. For surgery, each mouse was anesthetized with isoflurane or ketamine/xylazine and placed in a stereotaxic adapter. The electrodes were implanted over the left and right front lobes, the left and right parietal lobes, the cerebellum, and the sinus cavity using mounting screws. The electrodes were connected to a 6‐pin electrode pedestal and the headcap was secured using dental cement. After 7 days of recovery, simultaneous EEG recording and video monitoring were performed on Ceegraph Vision; Bio‐logic System Corporation and Natus recording systems. Following baseline recording for 2 days, mice were removed from recording for injection with TMX and recording was resumed at 7 days postinitial TMX injection. Signals were acquired at 256 Hz with simultaneous video monitoring. Data were filtered with a 1 Hz low pass filter, a 70 Hz high pass filter, and a notch filter at 60 Hz. Seizures were assessed manually.

Results {#acn3785-sec-0006}
=======

*Scn1b* null DS mice exhibit severe seizures beginning at \~postnatal day (P)10 and 100% lethality prior to \~P21.[10](#acn3785-bib-0010){ref-type="ref"} Our previous work suggested that aberrant brain development due to loss of *β*1‐mediated cell adhesion may underlie epileptogenesis in this model.[7](#acn3785-bib-0007){ref-type="ref"} To test this hypothesis, we crossed *Scn1b* ^Fl/Fl^ mice[9](#acn3785-bib-0009){ref-type="ref"} with a tamoxifen (TMX)‐inducible *Thy1‐Cre* (*Slick‐H*) strain.[11](#acn3785-bib-0011){ref-type="ref"} *Slick‐H* mice express Cre recombinase in response to TMX administration in *Thy1‐* expressing neurons, and are thus useful for separation of locally projecting GABA‐positive (+) neurons from locally and nonlocally projecting excitatory neurons. Constitutive *Thy1*‐driven YFP expression in *Slick‐H* mouse cortex showed laminar restriction within pyramidal neurons of layers 3, 5, and 6 (Fig. [1](#acn3785-fig-0001){ref-type="fig"}A), as shown previously.[11](#acn3785-bib-0011){ref-type="ref"} We co‐stained with anti‐GABA to examine whether GABA+ neurons are also targeted by *Thy1* promoter‐driven Cre recombinase in this strain. Neurons that were YFP+ were seldom GABA+ and *vice versa* (Fig. [1](#acn3785-fig-0001){ref-type="fig"}A, B, and F). We found similar results within the hippocampus, with dense labeling of the dentate gyrus and pyramidal neurons throughout the CA1, CA2, and CA3 regions, as well as in the subiculum, with limited overlap of YFP+ and GABA+ neurons (Fig. [1](#acn3785-fig-0001){ref-type="fig"}C and D).

![*Slick‐H* YFP expression in cortex, hippocampus, and subiculum. (A) *Slick‐H* mice express Cre and a YFP reporter (green) in projection neurons of the visual cortex with limited overlap with GABA+ cells (magenta). (B--E) *Slick‐H* mice express Cre and a YFP reporter in projection neurons of the hippocampus with limited overlap with GABA+ cells in the dentate gyrus (DG) (B), CA1 (C), CA3 (D), and subiculum (E). (F) Quantification of overlap between YFP and GABA+ cells across cortical layers (left) and hippocampal regions (right). YFP+ cell density in DG, CA1, and CA3 not quantified due to unclear cell boundaries with high density. Scale bars (in A and E) = 100 *μ*m.](ACN3-6-1121-g001){#acn3785-fig-0001}

To investigate the developmental dependence of epilepsy and SUDEP in response to *Scn1b* deletion, we administered TMX to *Slick‐H/Scn1b* ^*Fl/Fl*^ mice over various time ranges (P14--19, P42--117, and *P* \> 100) to ask whether induced *Scn1b* deletion in adult mice that had developed normally resulted in seizures and death. Regardless of age of administration, TMX treatment resulted in severe epilepsy and death in 100% of *Slick‐H/Scn1b* ^*Fl/Fl*^ mice compared to controls (*Slick‐H* negative *Scn1b* ^*Fl/Fl*^ mice injected with vehicle or *Slick‐H/Scn1b* ^*E/E*^ mice injected with TMX) within 20 days (Fig. [2](#acn3785-fig-0002){ref-type="fig"}A). All TMX‐treated *Slick‐H/Scn1b* ^*Fl/Fl*^ mice exhibited frequent spontaneous, behavioral seizures. To verify epileptic activity electrographically, we implanted three *Slick‐H/Scn1b* ^*Fl/Fl*^ mice, two *Slick‐H/Scn1b* ^*Fl/Fl*^ vehicle control mice and two *Slick‐H* negative *Scn1b* ^*Fl/Fl*^ control mice with EEG electrodes. Two days of baseline recording were followed by one IP administration of TMX or vehicle per day for four consecutive days to delete *Scn1b*. EEG recording was resumed 7 days after the initial TMX treatment (post‐TMX). We observed no seizures in *Slick‐H/Scn1b* ^*Fl/Fl*^ or control mice for the duration of baseline recording. In the *Slick‐H/Scn1b* ^*Fl/Fl*^ group, seizures were detected as early as 7 days post‐TMX (Fig. [2](#acn3785-fig-0002){ref-type="fig"}B and C). Two mice exhibited severe epilepsy and were euthanized for ethical reasons at day 8 and 9, respectively. The third mouse had a more gradual increase in seizure severity and was euthanized at 20 days post‐TMX due to morbidity. These results demonstrate that, although developmental brain defects are present in *Scn1b*‐DS mice, epileptogenesis and SUDEP are not the result of impaired brain development.

![Inducible deletion of *Scn1b* in adult projection neurons results in epilepsy and SUDEP. (A) Kaplan‐Meier survival curve of *Slick‐H/Scn1b* ^*Fl/Fl*^ mice injected with TMX at P14--19 (*n* = 5) or P42--117 (*n* = 15) compared to control mice: P14--19 *Slick‐H/Scn1b* ^*E/E*^ adolescent (*n* = 4) and *Slick‐H* negative *Scn1b* ^*Fl/Fl*^ P42--117 mice (*n* = 7). Survival of adult and adolescent *Slick‐H/Scn1b* ^*Fl/Fl*^ mice following TMX administration was not different (*P* = 0.71, Mantel‐Cox test). All *Slick‐H/Scn1b* ^*Fl/Fl*^ mice treated with TMX exhibited numerous behavioral seizures. (B) TMX‐induced *Scn1b* deletion in adult mice results in behavioral and electrographic seizures within 8 days of initial TMX administration. Control mice (black, *n* = 4) exhibited no seizures throughout the experiment while *Slick‐H/Scn1b* ^*Fl/Fl*^ mice that were administered TMX (blue squares, circles, and triangles represent individual mice; *n* = 3) experienced as many as 60 seizures/day. *Slick‐H* mice were euthanized at days 8, 9, and 20 due to morbidity. (C) Representative EEG traces of *Slick‐H/Scn1b* ^*Fl/Fl*^ and *Slick‐H/Scn1b* ^*E/E*^ mice. Left(L)/Right(R) and Frontal(F)/Parietal(P) screw electrode placement. Scale bar = 2000 *μ*V and 3 sec. (D) Expanded time scale of traces in panel C showing seizure onset. Scale bar = 2000 *μ*V and 0.25 sec.](ACN3-6-1121-g002){#acn3785-fig-0002}

Discussion {#acn3785-sec-0007}
==========

The results of this study demonstrate that epileptogenesis resulting from *Scn1b* loss‐of‐function is not due to impaired neuronal development. Furthermore, our data show that deletion of *Scn1b* in forebrain excitatory, but not inhibitory, neurons recapitulates the DS phenotype in mice. In previous work, targeted deletion of *Scn1a* in mouse inhibitory neurons phenocopied DS.[12](#acn3785-bib-0012){ref-type="ref"} In contrast, targeted deletion of *Scn1a* in excitatory neurons failed to recapitulate the DS phenotype and instead ameliorated disease severity when coupled with deletion in interneurons.[13](#acn3785-bib-0013){ref-type="ref"} Importantly, our work demonstrates that diverse mechanisms can lead to common neurological disease phenotypes.
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